Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Metagenomi"

3 News Found

Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics
Biotech | November 03, 2021

Moderna and Metagenomi partner to develop next-gen in vivo gene editing therapeutics

The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies

Gut microbiome as a tool in regenerative medicine
Biotech | May 07, 2022

Gut microbiome as a tool in regenerative medicine

Novel approach driven by GN Corp Japan with potentials in neurological illnesses

Scientists from BRICS work on genomic sequencing of Covid-19
Drug Approval | August 06, 2021

Scientists from BRICS work on genomic sequencing of Covid-19

Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging